Vaxcyte, Inc.
PCVX
Clasificación en acciones
#2112
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Precio por acción
$63.40
Última sincronización: 2026-10-16
Capitalización bursátil
$9.72B
Cambio (1 día)
-2.87%
Cambio (1 año)
49.56%
País
US
Comercio Vaxcyte, Inc. (PCVX)
Categoría
Healthcare
EPS de Vaxcyte, Inc. (PCVX)
EPS a fecha de June 2026 TTM: $-7.64
Según los últimos informes financieros y el precio de las acciones de Vaxcyte, Inc., el EPS actual de la empresa (TTM) es $-7.64. Al final del año 2023, la empresa tenía un EPS de $-4.14 un aumento con respecto a al EPS de 2022, que fue de $-3.44.
Historial de EPS de Vaxcyte, Inc. desde 2017 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-7.64 | 101.05% |
| 2024 | $-3.80 | -8.21% |
| 2023 | $-4.14 | 20.35% |
| 2022 | $-3.44 | 78.24% |
| 2021 | $-1.93 | -35.02% |
| 2020 | $-2.97 | -78.94% |
| 2019 | $-14.10 | 73.65% |
| 2018 | $-8.12 | 67.77% |
| 2017 | $-4.84 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -326.70% |
US
|
|
| $-7.98 | 4.45% |
US
|
|
| $-5.29 | -30.76% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -463.09% |
NL
|
